Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-prolactin Receptor Antibody LFA102

Known as: LFA102 
A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
  • V. Goffin
  • Pharmacology & therapeutics
  • 2017
    • Corpus ID: 43669906
In the era of precision medicine, the identification of new targets is a constant challenge to improve cancer therapy… Expand
2016
2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
Lessons Learned Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor… Expand
  • figure 2
  • figure 1
2016
2016
Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in… Expand
  • table 1
Review
2013
Review
2013
Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer
The prolactin (PRL)–prolactin receptor (PRLR) signaling complex has been implicated in the pathology of breast and prostate… Expand
  • figure 1
  • figure 2
2013
2013
Large Molecule Therapeutics Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA 102 , a Novel Potential Therapeutic for the Treatment of Breast Cancer
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL)may contribute to breast and prostate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
TITLE: Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, A Novel Potential Therapeutic for the Treatment of Breast Cancer AUTHORS AND AFFILIATIONS:
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Numerous lines of… Expand
  • table 1
2011
2011
Abstract DDT02-02: Preclinical development of LFA102, a highly potent and selective neutralizing antibody against the prolactin receptor
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The prolactin receptor (PRLR) is a class I cytokine… Expand
2011
2011
P3-17-09: Neutralizing the Prolactin Receptor with Therapeutic Antibody LFA102: A Novel Approach for the Treatment of Breast Cancer.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE